OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability